

WDN/GLB:gte 07/01/04
PATENT

Attorney Reference Number 7037-69151-01
Express Mail Label No. EV514603985US
Date of Deposit: July 1, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kim et al.

Application No. Not yet assigned

Filed: Herewith

Confirmation No. Not yet assigned

For: NOVEL ANTI-VIRAL VSF PROTEIN
AND HYBRIDOMA PRODUCING THE
SAME

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 7037-69151-01

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV514603985US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed July 1, 2004



MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Since the present application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55). Applicants will provide copies of such patents upon request.

10/500696

DN Rec'd PCT/PTO 01 JUL 2004

WDN/GLB:gte 07/01/04
PATENT

Attorney Reference Number 7037-69151-01
Express Mail Label No. EV514603985US
Date of Deposit: July 1, 2004

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of the transmittal letter for this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Gillian L. Bunker, Ph.D.
Registration No. 47,461

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

DRAFT Read/PDFTG 01 JUL 2004

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	7037-69151-01
Application Number	Not yet assigned 30696
Filed	Herewith
First Named Inventor	Kim
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

NOTE: Since this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,213,795	25 May 1993	Carlson <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 94/23041	13 Oct 1994	Miles <i>et al.</i>

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	KIM <i>et al.</i> "Characterization of viral inhibitory substance released from fused splenocyte" <i>Mol. Cells</i> , 7(2):165-169, 1997 (abstract only)
		SUH <i>et al.</i> "Enhancement of VP1-specific immune responses and protection against EMCVK challenge by co-delivery of IL-12 DNA with VP1 DNA vaccine" <i>Vaccine</i> , 19:1891-1898, 2001 (abstract only)
		WOOD <i>et al.</i> "An internal ribosome binding site can be used to select for homologous recombinants at an immunoglobulin heavy-chain locus" <i>Proc. Natl. Acad. Sci. USA</i> , 88(18):8006-8010, 1991

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.